124 related articles for article (PubMed ID: 36460206)
21. Heparan sulfate proteoglycans play a dual role in regulating fibroblast growth factor-2 mitogenic activity in human breast cancer cells.
Delehedde M; Deudon E; Boilly B; Hondermarck H
Exp Cell Res; 1996 Dec; 229(2):398-406. PubMed ID: 8986623
[TBL] [Abstract][Full Text] [Related]
22. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
23. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
24. Heparan sulfate proteoglycans as trastuzumab targets in anoikis-resistant endothelial cells.
Onyeisi JOS; Castanho de Almeida Pernambuco Filho P; de Araujo Lopes S; Nader HB; Lopes CC
J Cell Biochem; 2019 Aug; 120(8):13826-13840. PubMed ID: 30945340
[TBL] [Abstract][Full Text] [Related]
25. Alteration of endothelial proteoglycan and heparanase gene expression by high glucose, insulin and heparin.
Han J; Hiebert LM
Vascul Pharmacol; 2013; 59(3-4):112-8. PubMed ID: 23939434
[TBL] [Abstract][Full Text] [Related]
26. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
27. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
28. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
29. Isolation and characterization of ryudocan and syndecan heparan sulfate proteoglycans, core proteins, and cDNAs from a rat endothelial cell line.
Shworak NW; Kojima T; Rosenberg RD
Haemostasis; 1993 Mar; 23 Suppl 1():161-76. PubMed ID: 8495865
[TBL] [Abstract][Full Text] [Related]
30. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells.
Malavaki CJ; Roussidis AE; Gialeli C; Kletsas D; Tsegenidis T; Theocharis AD; Tzanakakis GN; Karamanos NK
FEBS J; 2013 May; 280(10):2477-89. PubMed ID: 23374223
[TBL] [Abstract][Full Text] [Related]
31. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer.
Fernández-Vega I; García O; Crespo A; Castañón S; Menéndez P; Astudillo A; Quirós LM
BMC Cancer; 2013 Jan; 13():24. PubMed ID: 23327652
[TBL] [Abstract][Full Text] [Related]
32. Suppressive effect of syndecan ectodomains and N-desulfated heparins on osteoclastogenesis via direct binding to macrophage-colony stimulating factor.
Kim JM; Lee K; Kim MY; Shin HI; Jeong D
Cell Death Dis; 2018 Nov; 9(11):1119. PubMed ID: 30389911
[TBL] [Abstract][Full Text] [Related]
33. Syndecan-1 Facilitates the Human Mesenchymal Stem Cell Osteo-Adipogenic Balance.
Yu C; Peall IW; Pham SH; Okolicsanyi RK; Griffiths LR; Haupt LM
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485953
[TBL] [Abstract][Full Text] [Related]
34. Spotlight on the Transglutaminase 2-Heparan Sulfate Interaction.
Furini G; Verderio EAM
Med Sci (Basel); 2019 Jan; 7(1):. PubMed ID: 30621228
[TBL] [Abstract][Full Text] [Related]
35. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
36. Syndecans reside in sphingomyelin-enriched low-density fractions of the plasma membrane isolated from a parathyroid cell line.
Podyma-Inoue KA; Hara-Yokoyama M; Shinomura T; Kimura T; Yanagishita M
PLoS One; 2012; 7(3):e32351. PubMed ID: 22396758
[TBL] [Abstract][Full Text] [Related]
37. Cancer cell exosomes depend on cell-surface heparan sulfate proteoglycans for their internalization and functional activity.
Christianson HC; Svensson KJ; van Kuppevelt TH; Li JP; Belting M
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17380-5. PubMed ID: 24101524
[TBL] [Abstract][Full Text] [Related]
38. Combinatorial roles of heparan sulfate proteoglycans and heparan sulfates in Caenorhabditis elegans neural development.
Kinnunen TK
PLoS One; 2014; 9(7):e102919. PubMed ID: 25054285
[TBL] [Abstract][Full Text] [Related]
39. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.
Ridgway LD; Wetzel MD; Ngo JA; Erdreich-Epstein A; Marchetti D
Mol Cancer Res; 2012 Jun; 10(6):689-702. PubMed ID: 22513363
[TBL] [Abstract][Full Text] [Related]
40. Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells: Syndecan-4 silencing and anoikis resistance.
Onyeisi JOS; Pernambuco Filho PCA; Mesquita APS; Azevedo LC; Nader HB; Lopes CC
Int J Biochem Cell Biol; 2020 Nov; 128():105848. PubMed ID: 32927086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
